Monogram Biosciences Inc.

William D. Young has served as Chief Executive Officer since November 1999 and has served as Chairman of the Board since May 1999. From March 1997 to October 1999, Mr. Young was Chief Operating Officer at Genentech, Inc., a biotechnology company. As COO at Genentech, Mr. Young was responsible for all of the company's development, operations and commercial functions. Mr. Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences and held various executive positions prior to becoming COO. Prior to joining Genentech, Mr. Young was employed by Eli Lilly and Company for 14 years. Mr. Young is a member of the board of directors of Biogen IDEC, Inc., Human Genome Sciences, Inc. and Theravance, Inc. He received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University.

Alfred G. Merriweather is Senior Vice President, Chief Financial Officer. From December 2001 to December 2004, Mr. Merriweather served as Vice President, Finance, Chief Financial Officer and Secretary of ACLARA. From 1999 to 2001, he was Vice President and Chief Financial Officer for Citadon, Inc., a software company. From 1996 to 1999, Mr. Merriweather was Vice President of Finance and Chief Financial Officer of Symphonix Devices, Inc., a manufacturer of implantable medical devices. From 1993 to 1996, Mr. Merriweather was Vice President of Finance and Chief Financial Officer of LipoMatrix, Inc., a medical device company based in Neuchatel, Switzerland. Prior to that, Mr. Merriweather was Vice President of Finance and Chief Financial Officer of Laserscope, a manufacturer of surgical laser systems. Mr. Merriweather holds a BA from the University of Cambridge, England.

Christos J. Petropoulos, PhD is Vice President of Research and Development, Virology and Chief Scientific Officer. He joined Monogram as Director of Research and Development in August 1996, became Senior Director of Research and Development in September 1997, was named Vice President, Research and Development in November 1999 and was named Vice President, Research and Development, Virology and Chief Scientific Officer in December 2004. From 1992 to 1996, Dr. Petropoulos was a scientist at Genentech where he headed the Molecular Virology Laboratory and the Research Virology and Molecular Detection Laboratories from 1994 to 1996. Dr. Petropoulos received his PhD in molecular and cell biology from Brown University.

William J. Welch has served as our Senior Vice President and Chief Commercial Officer since September 2005. From 1998 to 1999 and from 2001 to August 2005, Mr. Welch was with LaJolla Pharmaceutical, Inc., most recently as Vice President, Sales & Marketing. From 1999 to 2001, Mr. Welch was Vice President of Global Marketing for Dade Behring MicroScan where he managed marketing and strategic development for a $150 million business. From 1993 to 1998, Mr. Welch held a number of management positions with Abbott Laboratories, including General Manager of the Ambulatory Infusion Systems Division. Mr. Welch holds a BS from the University of California at Berkeley and an MBA from Harvard University.

Kathy L. Hibbs is Senior Vice President, General Counsel, and joined in April 2001. Prior to joining Monogram, Ms. Hibbs was Vice President and General Counsel for Multitude, Inc., an Internet telecommunications company. Prior to that, from 1996 to 2000, she served as Senior Corporate Counsel at Varian Medical Systems, Inc., a leading manufacturer of integrated cancer therapy systems. At Varian, she was responsible for numerous legal matters including regulatory compliance, employment law, litigation and SEC reporting. Before her employment with Varian, Ms. Hibbs worked as a litigator for two California law firms and dealt with various legal issues, including civil rights and securities law. She received her JD degree from the University of California, Hastings College of Law, and her bachelor's degree in political science from the University of California, Riverside.

Jeannette M. Whitcomb, PhD is Vice President of Operations. She joined Monogram as one of the first scientists in the Research and Development department in 1996, transitioned to the Operations group in 2002 and was named Vice President of Operations in June 2003. Prior to joining Monogram, Dr. Whitcomb was a Postdoctoral Fellow in Dr. Stephen H. Hughes' lab at the National Cancer Institute — Frederick Cancer Research and Development Center. Prior to that, she was a Fogerty Fellow in Dr. Peter A. Cerutti's lab at the Swiss Institute for Experimental Cancer Research in Lausanne, Switzerland. Dr. Whitcomb received her bachelor's degree in biology from Widener University in Chester, Pennsylvania and her PhD in microbiology and immunology from Temple University School of Medicine in Philadelphia.

Kenneth N. Hitchner is Vice President of Pharmaceutical Collaborations. He joined Monogram as Director of Project Management in May 1999 and was named Vice President of Pharmaceutical Collaborations in October 2003. From December 1997 to May 1999, Mr. Hitchner was the Director of Project Management at Gilead Sciences. Prior to Gilead, he was with Genentech for 15 years and held a number of positions including Director of Product Development and Global Project Leader. Mr. Hitchner received his bachelor's degree in zoology from DePauw University and a master's degree in biology from San Francisco State University.

Michael P. Bates, MD is Vice President of Clinical Research. He joined our Clinical Research group as Medical Director in January 2001, was promoted to Senior Director in 2003 and was named Vice President of Clinical Research in June 2004. Prior to joining Monogram, Dr. Bates completed his internship and residency in Internal Medicine at the University of California, San Francisco, before pursuing fellowship training in Cardiology at Duke University in Durham, North Carolina, and in Infectious Diseases at the University of Washington in Seattle, Washington. Following two years on the junior faculty at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, Dr. Bates moved to industry. Dr. Bates was Regional Medical Director/Medical Liaison for Roche, focusing on virology from February 1999 to December 2000.

Michael G. Vicari is our Vice President of Sales. He joined Monogram in February, 2006 as Senior Director of Sales, and was named Vice President of Sales in March 2007. He currently oversees our Sales, Strategic Accounts, and Payer Relations functions. Mike brings 25 years of industry experience in sales, training, payer relations, and sales management. He has held senior sales management positions at biotechnology companies Genentech, Nuerex, Medimmune, and Corixa. He holds a BS in Organizational Behavior from University of San Francisco.

Patricia Wray is the Vice President, Human Resources. She has overseen Monogram's Human Resources function in a number of capacities since 1998. Prior to joining Monogram, Ms. Wray held a number of postions at Genentech including Director of Employee Relations and Training. Before her employment with Genentech, Ms. Wray worked as Employee Relations Manager at Hewlett Packard in both the Networking and Analytical Instrument Divisions. She received her Masters degree from Michigan State University, and a BS in Horticulture from University of Delaware.

Timothy G. Henn joined Monogram in April 2007 as our Vice President, Finance. Mr. Henn brings more than 20 years of finance experience, including roles at several public companies, and has been instrumental in numerous strategic, financial and operational activities. Most recently he served as Vice President, Finance and Administration for Dynavax Technologies Corporation. Prior to Dynavax, Mr. Henn served as Senior Vice President, Finance and Corporate Controller at Incyte Corporation. Mr. Henn received his M.B.A. from Golden Gate University and his B.S. in accounting from the University of Illinois.

Ms. Kepner joined us as a director in May 1998. She was with Invemed from 1978 to 2000, where she has served in a variety of capacities. Prior to retiring from Invemed in December 2000, Ms. Kepner served as Executive Vice President and Corporate Finance Director until December 31, 2000. Ms. Kepner also served as a director of Invemed until December 2000. Ms. Kepner currently serves as a director of Monogram Biosciences, Inc. and is the Chairman of the Board of Quipp, Inc.

David H. Persing, MD, PhD has served as a director since December 2000. Dr. Persing received his BA degree in biochemistry from San Jose State University, and his MD and PhD (biochemistry and biophysics) concurrently from the University of California, San Francisco. After completing his residency in clinical pathology and fellowship training at Yale University in 1989, Dr. Persing was appointed to the medical and research staff of the Mayo Clinic, where he became Director of the Molecular Microbiology Laboratory and an Associate Professor at the Mayo Medical School. In August 1999, Dr. Persing became employed at Corixa Corporation, a research and development-based biotechnology company, where he is Vice President of Discovery Research, as well as a Principal Investigator in the Infectious Disease Research Institute, a non-profit research organization. Dr. Persing serves on the board of directors of Cepheid.

William J. Jenkins,M.D. has been a non-executive director since July 2000. He serves on our Audit and Nominating and Corporate Governance Committees. Until March 1999, Dr. Jenkins was the Head of Clinical Development and Regulatory Affairs Worldwide and a member of the Executive Committee at Novartis Pharma AG in Switzerland. Dr. Jenkins is a consultant to the pharmaceutical industry and to private equity and venture capital firms and a non-executive director of BTG plc and Monogram Biosciences, Inc. and a member of the Scientific Advisory Boards of BBBiotech Ventures II, Evotec, AG (where he serves as chairman) and Nicholas Piramal India Ltd.. Dr. Jenkins holds a B.A., M.D., and other advanced degrees from Cambridge University in England, as well as advanced degrees from the Royal College of Physicians, United Kingdom and from London University.

Edmon R. Jennings has served as a director since May 2001. Since July 2003, Mr. Jennings has served as President and CEO of Angiogenix, Inc., a biopharmaceutical company. From February 2000 to June 2003, Mr. Jennings was Chief Commercialization Officer at Pain Therapeutics, Inc., a medical research and development company. From 1985 to 2000, Mr. Jennings held senior management positions at Genentech, Inc., including Vice President of Corporate Development, Vice President of Sales and Marketing and Vice President of Sales. Prior to Genentech, Mr. Jennings held positions for 12 years with Bristol-Myers Oncology and Bristol Laboratories, both of which were divisions of Bristol-Myers (now Bristol-Myers Squibb), a pharmaceutical company. Mr. Jennings received his BA in liberal arts from the University of Michigan at Ann Arbor.

John D. Mendlein, PhD, JD has served as a director since December 2004. Dr. Mendlein was a member of ACLARA Biosciences, Inc.'s board of directors from April 2003 to December 2004. Dr. Mendlein is Chief Executive Officer of Compound Therapeutics. Dr. Mendlein is Chairman of Affinium Pharmaceuticals, Inc., a drug discovery company, and also served as Chief Executive Officer from November 2000 to June 2005. Prior to joining Affinium, Dr. Mendlein served as Chief Knowledge Officer, General Counsel and Senior Vice President, Intellectual Property of Aurora Biosciences Corporation, from 1996 until 2000. Dr. Mendlein holds a PhD in physiology and biophysics from the University of California, Los Angeles and a JD degree from the University of California, Hastings College of Law.